ImmunityBio IBRX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
ImmunityBio (IBRX) Business Model and Operations Summary
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Key Insights
ImmunityBio (IBRX) Core Market Data and Business Metrics
Latest Closing Price
$2.96Market Cap
$2.52 BillionPrice-Earnings Ratio
-10.57Total Outstanding Shares
853.44 Million SharesTotal Employees
680Dividend
No dividendIPO Date
March 10, 2021SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
3530 John Hopkins Court, San Diego, CA, 92121
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $15.58 Million |
| Net Cash Flow From Operating Activities | $-98.76 Million |
| Net Cash Flow From Operating Activities, Continuing | $-98.76 Million |
| Net Cash Flow, Continuing | $-18.15 Million |
| Net Cash Flow From Investing Activities, Continuing | $65.03 Million |
| Net Cash Flow From Financing Activities, Continuing | $15.58 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Interest Expense, Operating | $29.32 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss | $-85.75 Million |
| Basic Earnings Per Share | $-0.12 |
| Net Income/Loss Available To Common Stockholders, Basic | $-85.73 Million |
| Cost Of Revenue | $0 |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-85.64 Million |
| Comprehensive Income/Loss Attributable To Parent | $-85.62 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-23,000 |
| Other Comprehensive Income/Loss | $111,000 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Equity | $-744.16 Million |
| Noncurrent Assets | $201.42 Million |
| Liabilities And Equity | $364.57 Million |
| Current Liabilities | $60.96 Million |
| Current Assets | $163.15 Million |
| Equity Attributable To Parent | $-745.15 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||